The effectiveness of non-clinical drug safety predictions is enhanced by the adoption of three-dimensional (3D) cellular models. 3D bioprinting enables the generation of complex models with spatial ...

Five years ago, Neil Kumar, Ph.D., quit his job at Third Rock Ventures to start a new kind of biotech company. The idea was "Moneyball" for biotech—to pick up potential rare disease treatments ...

Bitterroot Bio Inc. presented data on an anti-CD47 hybrid protein, BRB-002, tested in a murine model of atherosclerosis. BRB-002 was tested at 2.5 or 10 mg/kg i.p. 3x/week after a high-fat diet.

BLR Bio LLC has announced new data on BLR-200, its lead compound for systemic sclerosis and lung fibrosis. In the new study, BLR-200 demonstrated the ability to reduce key disease tissue markers for ...